Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

NCT00950742 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Trastuzumab
DRUG: BIBW 2992

Sponsor

Boehringer Ingelheim